Denmark equities were higher at the close on Friday, as gains in the Consumer Goods, Healthcare and Financials sectors ...

Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...

Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...

Zealand Pharma is working on the next-gen weight-loss treatment. Its Petrelintide showed promising results in a Phase 1b ...

Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for ...

Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...

Type 1 Diabetes Market Set To Eyewitness Substantial Growth By 2024-2031: Sanofi, Wockhardt Ltd., Ypsomed AG, Novartis Type 1 Diabetes Market is expected to reach USD 24.36 Bn by 2031, exhibiting a ...

After third-party manufacturing issues led to a December rejection of Zealand Pharma’s pediatric congenital hyperinsulinism (CHI) candidate, the Danish pharma’s latest snub seems to come down to ti | ...

Zealand Pharma A/S (ZEAL) reported that Boehringer Ingelheim announced that the U.S. Food and Drug Administration has granted ...